
MyFastRx Review
Best for: Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate.
MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles. Compounded semaglutide runs $169/mo standard, dropping to $99/mo on a 12-month prepay; tirzepatide is $249/mo standard, down to $149/mo on 12 months — all doses priced the same with a SAVE70 first-month promo. It accepts no insurance and ships nationwide; LegitScript-listed and HIPAA-compliant.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
MyFastRx is a solid telehealth option with balanced features and pricing.
MyFastRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How we scored MyFastRx
Each dimension is scored algorithmically from MyFastRx’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.3/10At $99/mo, MyFastRx runs about 42% below the $170 median for GLP-1 providers. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
7.1/10MyFastRx offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
6.4/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
6.3/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-06).
Accessibility10%
7.6/10MyFastRx treats patients in all 50 states. Insurance pathways are offered for eligible patients.
Support10%
4.9/10MyFastRx provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this MyFastRx review
Last checked 2026-06-06- Confirmed current pricing across 4 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications MyFastRx offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Ready to get started?
Plans and promotions change often — check MyFastRx's current pricing and active discounts before you decide.
What we like
- Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
- LegitScript certified
- All doses priced the same — no cost escalation as you titrate up
- First-month promo discount lowers the trial barrier
Watch-outs
- States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
- Corporate address and medical director not published
- Pharmacy partner not named — only 'state-licensed pharmacies'
- Cash-pay only — no insurance billing
- Bundle savings require a large upfront commitment (12 months billed at once)
MyFastRx: the cheapest compounded GLP-1 if you'll pay a year upfront
MyFastRx is a cash-pay telehealth platform built around one idea: get you approved fast and reward you for committing long-term. Its headline rate of $99 a month for compounded semaglutide is among the lowest published prices we track — but that number only appears if you prepay a full twelve months at once. Pay month to month and you'll spend considerably more. So the real question isn't whether MyFastRx is cheap; it's whether you're ready to bet a year of treatment on a provider that keeps a lot of its operation undisclosed. For the right patient, the math is genuinely attractive. For everyone else, the trade-offs deserve a hard look.
How the bundle pricing actually works
MyFastRx uses a tiered ladder where the price drops the longer you commit. Compounded semaglutide starts at a standard monthly rate and steps down through three-month and six-month plans to $99 a month on the twelve-month bundle. Compounded tirzepatide follows the same structure at a higher price point, landing in the mid-hundreds per month on the full-year plan. A first-month promo code (SAVE70) knocks the opening payment down to lower the trial barrier.
The catch is right there in the structure: those best-case numbers are billed upfront, all twelve months at once. That's a large single charge to a provider whose pharmacy partner and medical director aren't named publicly. The standard month-to-month rate is real and still reasonable, but it's nowhere near the figure the homepage leads with. For context, the $170 category median sits between MyFastRx's standard and bundle rates — so this provider is a genuine value play only if you go long.
Flat dosing is the underrated win here
One feature that quietly favors patients: every dose costs the same. Many compounded-GLP-1 sellers raise your monthly bill as you titrate up to higher strengths, which punishes you precisely as the medication starts working. MyFastRx prices all doses identically. Whether you're starting low or have climbed to a maintenance dose, your rate doesn't move. Over a year of dose escalation, that flat structure can save real money compared with a provider that charges by strength — and it makes budgeting predictable, which matters when you've already prepaid.
What you actually get
- Compounded semaglutide or compounded tirzepatide, injectable
- A doctor consultation included — no separate visit fee
- Free discreet shipping nationwide
- The same price at every dose as you titrate up
- A tiered discount that rewards 3-, 6-, or 12-month commitments
The medications and how they're dispensed
MyFastRx deals exclusively in compounded versions of semaglutide and tirzepatide — the same active ingredients as the brand-name injectables, prepared by a compounding pharmacy rather than the original manufacturer. There's no brand-name Wegovy, Zepbound, or Ozempic option here, and no oral pill; this is injectable compounded medication only. The consultation and shipping are bundled into the price, so the monthly figure is close to your all-in cost rather than a teaser that balloons at checkout.
What MyFastRx will not tell you is which pharmacy makes your medication. The site references 'state-licensed pharmacies' but names no specific 503A or 503B partner. For a compounded product — where the pharmacy IS the quality control — that opacity is a meaningful gap. You're trusting the platform's vetting without being able to verify the source yourself.
Trust and safety: a mixed, medium-confidence picture
On the positive side, MyFastRx is LegitScript-certified, which is a real credential — it means a third party reviewed the operation for compliance with pharmacy and telehealth rules. The platform is HIPAA-compliant and operates as a registered corporate entity. There are no FDA warning letters on file against it in our records, and it claims to work through licensed U.S. providers across all states.
But the disclosure gaps keep this from being a high-confidence pick. The specific states served aren't enumerated. No medical director is named. No corporate address is published. The pharmacy partner is anonymous. None of these is individually disqualifying, but together they mean you're extending more trust than a fully transparent provider would ask for. Our scoring methodology treats undisclosed oversight as a real cost, and MyFastRx pays it. We'd rate the verification here as medium — the pricing is verbatim and the LegitScript listing checks out, but the people and places behind the brand stay in the shadows.
Who should choose it — and who should skip it
Choose MyFastRx if you're a cash-pay patient who has already decided you're in this for the long haul, you're comfortable paying a full year upfront, and the lowest possible monthly rate is your top priority. The flat per-dose pricing and bundled consult make it especially good for someone who expects to titrate to a higher maintenance dose and wants their cost locked in.
Skip it if you want to start month-to-month and see how you respond before committing — the standard rate erases much of the advantage. Skip it if you need insurance billing, since MyFastRx is cash-pay only and won't coordinate coverage. And skip it if undisclosed oversight is a dealbreaker for you: a named pharmacy and a published medical director are things some competitors offer, and if that transparency matters, you can find it elsewhere.
Bottom line
MyFastRx earns its place as a value option for committed, cash-pay GLP-1 patients. The twelve-month bundle rate of $99 for compounded semaglutide is legitimately competitive, and flat dosing is a patient-friendly touch too few providers offer. But the price you see advertised is the long-commitment price, and the company asks for that commitment while keeping its pharmacy, medical leadership, and state footprint private. If you go in clear-eyed — prepaying a year to a LegitScript-listed but partly opaque platform in exchange for a low rate — it can be a smart deal. If any of that gives you pause, a more transparent provider is worth the few extra dollars.
Shopping around? Telos Rx ($49/month) and bmiMD ($99/month) are the nearest alternatives to MyFastRx in our rankings.
Ready to start with MyFastRx?
Starting at $99/month. See current pricing and start your free consultation.
Alternatives to MyFastRx
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this MyFastRx review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with MyFastRx?
Starting at $99/month. See current pricing and start your free consultation.